|本期目录/Table of Contents|

[1]张娅洁,王慧媛,陈应之,等.经穿膜肽与PEG修饰的核糖体失活蛋白Gelonin抗肿瘤作用的研究[J].天津医科大学学报,2015,21(05):369-374.
　ZHANG Ya-jie,WANG Hui-yuan,CHEN Ying-zhi,et al.Study on cell-penetrating peptide modified and PEGylated ribosome inactive protein Gelonin[J].Journal of Tianjin Medical University,2015,21(05):369-374.
点击复制

经穿膜肽与PEG修饰的核糖体失活蛋白Gelonin抗肿瘤作用的研究(PDF)
分享到：

《天津医科大学学报》[ISSN:1006-8147/CN:12-1259/R]

卷:
21卷
期数:
2015年05期
页码:
369-374
栏目:
基础医学
出版日期:
2015-09-20

文章信息/Info

Title:
Study on cell-penetrating peptide modified and PEGylated ribosome inactive protein Gelonin
文章编号:
1006-8147（2015）05-0369-06
作者:
张娅洁1; 2;  王慧媛2;  陈应之2;  汤懿斯2; 3;  杨志民1; 4*;  黄永焯2*
（1. 天津医科大学药学院，天津市临床药物关键技术重点实验室，天津 300070； 2.中国科学院上海药物研究所，上海 201203 ；3.广州中医药大学热带医学研究所，广州 510405；4.美国密西根大学药学院, 美国密西根州 48109 ）

Author(s):
?ZHANG Ya-jie1; 2;  WANG Hui-yuan2;  CHEN Ying-zhi2;  TANG Yi-si2; 3;  YANG Victor C1; 4*;  HUANG Yong-zhuo2*
（1. School of Pharmacy,Tianjin Medical University, Tianjin 300070, China；2.Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China；3.Teopical Medicine Institute, Guangzhou University of Chinese Medicine, Guangzhou 510405, China；4.College of Pharmacy, University of Michigan, Michigan 48109, USA）

关键词:
核糖体失活蛋白; 聚乙二醇; 低分子量鱼精蛋白; 抗肿瘤; Gelonin
Keywords:
ribosome inactivating protein;  polyethylene glycol;  low molecular weight protamine;  anti-tumor;  gelonin
分类号:
R9
DOI:
-
文献标志码:
A
摘要:
目的：通过对核糖体失活蛋白Gelonin进行化学修饰，利用穿膜肽和聚乙二醇（PEG）偶联来提高其到达肿瘤部位和进入肿瘤细胞的能力，使Gelonin更高效地发挥抑瘤作用。方法：利用FPLCSuperdex75分子筛预装柱纯化系统对所修饰的Gelonin进行纯化后，并在不同细胞系测试细胞毒性；通过倒置荧光显微镜、流式细胞分析技术等对药物进入纤维肉瘤细胞HT1080的能力进行评价；采用小动物活体成像技术考察了药物体系在荷瘤动物体内的分布情况。结果：采用分子筛色谱纯化可以得到纯度相对较高的修饰产物，其毒性较无修饰的Gelonin强，且在HT1080细胞系作用最明显；细胞摄取结果显示，与未修饰的Gelonin相比，该药物体系具有更高的细胞摄取效率；动物成像结果表明，PEG5000修饰可以改变Gelonin在动物体内的分布情况，增加在肿瘤的药物蓄积。结论：穿膜肽和PEG5000修饰后的Gelonin有较高的肿瘤细胞摄取和杀伤能力，药物在肿瘤的蓄积量较高，从而增强了药物的其抑瘤效果。
Abstract:
Objective ：To improve anti-tumor effect of gelonin, by modifying the plant-sourced RIP by chemically conjugating a cell-penetrating peptide and polyethylene glycol (PEG). Methods：Purified protein was obtained after performed on FPLC (Fast protein liquid chromatography) Superdex75 column. Cytotoxicity was detected by MTT assay. The cellular uptake by HT1080 cells was studied by using inverted fluorescence microscopy and flow cytometry. In-vivo imaging technology was utilized for investigation of the in-vivo drug distribution in the HT1080 tumor-bearing mice. Results：The modified product was purified by using gel filtration chromatergraphy. Moreover, compared with native gelonin, the cytotoxicity of modified protein was increased, especially in HT1080, presumably due to the enhanced cellular uptake. The in-vivo imaging results suggested that drug accumulation in tumor was improved by PEGylation. Conclusion： Modified gelonin can improve cell penetration and cytotoxicity in tumor cells. PEGylation can increase tumor accumulation of the protein drug, and thereby enhance its anti-tumor effect.

参考文献/References:

[1]Antignani A, Fitzgerald D. Immunotoxins: the role of the toxin[J].Toxins (Basel),2013,5(8):1486

[2]Atkinson S F, Bettinger T, Seymour L W, et al. Conjugation of folate via gelonin carbohydrate residues retains ribosomal-inactivating properties of the toxin and permits targeting to folate receptor positive cells[J].J Biol Chem,2001,276(30):27930

[3]Byun Y, Singh V K, Yang V C. Low molecular weight protamine: a potential nontoxic heparin antagonist[J].Thromb Res, 1999, 94(1):53

[4]Chang L C, Liang J F, Lee H F, et al. Low molecular weight protamine (LMWP) as nontoxic heparin/low molecular weight heparin antidote (II): in vitro evaluation of efficacy and toxicity[J].AAPS PharmSci, 2001, 3(3):E18

[5]Chang L C, Lee H F, Yang Z, et al. Low molecular weight protamine (LMWP) as nontoxic heparin/low molecular weight heparin antidote (I): preparation and characterization[J].AAPS PharmSci,2001,3(3):E17

[6]Lee L M, Chang L C, Wrobleski S, et al. Low molecular weight protamine as nontoxic heparin/low molecular weight heparin antidote (III): preliminary in vivo evaluation of efficacy and toxicity using a canine model[J].AAPS PharmSci,2001,3(3):E19

[7]Tsui B, Singh V K, Liang J F, et al. Reduced reactivity towards anti-protamine antibodies of a low molecular weight protamine analogue[J].Thromb Res,2001,101(5):417

[8]Liang J F, Zhen L, Chang L C, et al. A less toxic heparin antagonist--low molecular weight protamine[J].Biochemistry (Mosc), 2003, 68(1):116

[9]Abuchowski A, van Es T, Palczuk N C, et al. Alteration of immunological properties of bovine serum albumin by covalent attachment of polyethylene glycol[J].J Biol Chem,1977,252(11):3578

[10]Abuchowski A, Mccoy J R, Palczuk N C, et al. Effect of covalent attachment of polyethylene glycol on immunogenicity and circulating Life of bovine liver catalase[J].J Biol Chem,1977,252(11):3582

[11]Stirpe F, Olsnes S, Pihl A. Gelonin, a new inhibitor of protein synthesis, nontoxic to intact cells. Isolation, characterization, and preparation of cytotoxic complexes with concanavalin A[J].J Biol Chem,1980,255(14):6947

[12]Puri M, Kaur I, Perugini M A, et al. Ribosome-inactivating proteins: current status and biomedical applications[J].Drug Discov Today,2012,17(13/14):774

[13]Langel ü.Cell-Penetrating peptides:methods and protocols[M]. [S.l.]:human press,2011:45-62

[14]Schwarze S R, Ho A, Vocero-Akbani A, et al. In vivo protein transduction: delivery of a biologically active protein into the mouse[J].Science,1999,285(5433):1569

[15]Huang Y, Jiang Y, Wang H, et al. Curb challenges of the "Trojan Horse" approach: smart strategies in achieving effective yet safe cell-penetrating peptide-based drug delivery[J].Adv Drug Deliv Rev,2013,65(10):1299

[16]Dietz G P, B?hr M. Delivery of bioactive molecules into the cell: the Trojan horse approach[J].Mol Cell Neurosci,2004,27(2):85

[17]Shin M C, Zhang J, Min K A, et al. Combination of antibody targeting and PTD-mediated intracellular toxin delivery for colorectal Cancer therapy[J].J Control Release,2014,194:197

[18]Shin M C, Zhao J, Zhang J, et al. Recombinant TAT-gelonin fusion toxin: synthesis and characterization of heparin/protamine-regulated cell transduction[J].J Biomed Mater Res A,2015,103(1):409

[19]Hu M, Chen P, Wang J, et al. Site-specific conjugation of HIV-1 tat peptides to IgG: a potential route to construct radioimmunoconjugates for targeting intracellular and nuclear epitopes in Cancer[J].Eur J Nucl Med Mol Imaging,2006,33(3):301

[20]Hu M, Wang J, Chen P, et al. HIV-1 tat peptide immunoconjugates differentially sensitize breast Cancer cells to selected antiproliferative agents that induce the cyclin-dependent kinase inhibitor p21WAF-1/CIP-1[J].Bioconjug Chem,2006,17(5):1280

[21]Hu M, Chen P, Wang J, et al. 123I-labeled HIV-1 tat peptide radioimmunoconjugates are imported into the nucleus of human breast Cancer cells and functionally interact in vitro and in vivo with the cyclin-dependent kinase inhibitor, p21(WAF-1/Cip-1)[J].Eur J Nucl Med Mol Imaging,2007,34(3):368

[22]Harada H, Hiraoka M, Kizaka-Kondoh S. Antitumor effect of TAT-oxygen-dependent degradation-caspase-3 fusion protein specifically stabilized and activated in hypoxic tumor cells[J].Cancer Res,2002,62(7):2013

[23]Yu Z, Wu J, Wu S, et al. A recombinant cell-permeable p53 fusion protein is selectively stabilized under hypoxia and inhibits tumor cell growth[J].Cancer Lett,2009,279(1):101

[24]Lee J H, Lu H. Chimeric p53 as an alternative therapy for hypoxic tumors[J].Cancer Biol Ther,2011,11(1):108

相似文献/References:

备注/Memo

备注/Memo:
基金项目 国家自然科学基金资助项目（81172996, 81373357, 81361140344, 81422048）

作者简介 张娅洁（1988-），女，硕士在读，研究方向：药剂学；通信作者：杨志民，E-mail：vcyang@med.umich.edu；黄永焯，E-mail：yzhuang@simm.ac.cn 。



更新日期/Last Update: 2015-09-22